147 related articles for article (PubMed ID: 8698542)
1. Intermediate cancer biomarkers and their use in beta-carotene studies in humans.
Gerster H
Int J Vitam Nutr Res; 1996; 66(1):3-18. PubMed ID: 8698542
[TBL] [Abstract][Full Text] [Related]
2. Risk biomarkers and current strategies for cancer chemoprevention.
Kelloff GJ; Boone CW; Crowell JA; Nayfield SG; Hawk E; Malone WF; Steele VE; Lubet RA; Sigman CC
J Cell Biochem Suppl; 1996; 25():1-14. PubMed ID: 9027592
[TBL] [Abstract][Full Text] [Related]
3. Cancer risk factors for selecting cohorts for large-scale chemoprevention trials.
Greenwald P
J Cell Biochem Suppl; 1996; 25():29-36. PubMed ID: 9027595
[TBL] [Abstract][Full Text] [Related]
4. Large bowel adenomas: markers of risk and endpoints.
Baron JA
J Cell Biochem Suppl; 1996; 25():142-8. PubMed ID: 9027611
[TBL] [Abstract][Full Text] [Related]
5. The association between lung and prostate cancer risk, and serum micronutrients: results and lessons learned from beta-carotene and retinol efficacy trial.
Goodman GE; Schaffer S; Omenn GS; Chen C; King I
Cancer Epidemiol Biomarkers Prev; 2003 Jun; 12(6):518-26. PubMed ID: 12814997
[TBL] [Abstract][Full Text] [Related]
6. G-actin as a risk factor and modulatable endpoint for cancer chemoprevention trials.
Hemstreet GP; Rao J; Hurst RE; Bonner RB; Waliszewski P; Grossman HB; Liebert M; Bane BL
J Cell Biochem Suppl; 1996; 25():197-204. PubMed ID: 9027619
[TBL] [Abstract][Full Text] [Related]
7. Chemoprevention trials in the cervix: design, feasibility, and recruitment.
Mitchell MF; Hittelman WN; Lotan R; Nishioka K; Tortolero-Luna G; Richards-Kortum R; Hong WK
J Cell Biochem Suppl; 1995; 23():104-12. PubMed ID: 8747384
[TBL] [Abstract][Full Text] [Related]
8. Randomized trial of supplemental beta-carotene to prevent second head and neck cancer.
Mayne ST; Cartmel B; Baum M; Shor-Posner G; Fallon BG; Briskin K; Bean J; Zheng T; Cooper D; Friedman C; Goodwin WJ
Cancer Res; 2001 Feb; 61(4):1457-63. PubMed ID: 11245451
[TBL] [Abstract][Full Text] [Related]
9. Lung cancer chemoprevention: an integrated approach.
Lippman SM; Spitz MR
J Clin Oncol; 2001 Sep; 19(18 Suppl):74S-82S. PubMed ID: 11560978
[TBL] [Abstract][Full Text] [Related]
10. Perspectives on surrogate end points in the development of drugs that reduce the risk of cancer.
Kelloff GJ; Sigman CC; Johnson KM; Boone CW; Greenwald P; Crowell JA; Hawk ET; Doody LA
Cancer Epidemiol Biomarkers Prev; 2000 Feb; 9(2):127-37. PubMed ID: 10698472
[TBL] [Abstract][Full Text] [Related]
11. Prostatic intraepithelial neoplasia (PIN) and other prostatic lesions as risk factors and surrogate endpoints for cancer chemoprevention trials.
Bostwick DG; Aquilina JW
J Cell Biochem Suppl; 1996; 25():156-64. PubMed ID: 9027613
[TBL] [Abstract][Full Text] [Related]
12. Lung cancer: chemoprevention and intermediate effect markers.
Tockman MS
IARC Sci Publ; 2001; 154():257-70. PubMed ID: 11220665
[TBL] [Abstract][Full Text] [Related]
13. Chemoprevention of oral cancer: the need for effective biological monitoring.
Pillai MR; Ravi D; Nair MK
Singapore Dent J; 1997 Aug; 22(1):6-12. PubMed ID: 10597170
[TBL] [Abstract][Full Text] [Related]
14. Lower prostate cancer risk in men with elevated plasma lycopene levels: results of a prospective analysis.
Gann PH; Ma J; Giovannucci E; Willett W; Sacks FM; Hennekens CH; Stampfer MJ
Cancer Res; 1999 Mar; 59(6):1225-30. PubMed ID: 10096552
[TBL] [Abstract][Full Text] [Related]
15. PASSCLAIM--diet-related cancer.
Rafter J; Govers M; Martel P; Pannemans D; Pool-Zobel B; Rechkemmer G; Rowland I; Tuijtelaars S; van Loo J
Eur J Nutr; 2004 Jun; 43 Suppl 2():II47-II84. PubMed ID: 15221354
[TBL] [Abstract][Full Text] [Related]
16. Biomarker intermediate endpoints and cancer prevention.
Meyskens FL
J Natl Cancer Inst Monogr; 1992; (13):177-81. PubMed ID: 1389691
[TBL] [Abstract][Full Text] [Related]
17. Chemoprevention of lung cancers: lessons from CARET, the beta-carotene and retinol efficacy trial, and prospects for the future.
Omenn GS
Eur J Cancer Prev; 2007 Jun; 16(3):184-91. PubMed ID: 17415088
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness of beta-carotene in cancer chemoprevention.
Toma S; Losardo PL; Vincent M; Palumbo R
Eur J Cancer Prev; 1995 Jun; 4(3):213-24. PubMed ID: 7647689
[TBL] [Abstract][Full Text] [Related]
19. Chemoprevention in head and neck cancer.
Heyne KE; Lippman SM; Hong WK
Hematol Oncol Clin North Am; 1991 Aug; 5(4):783-95. PubMed ID: 1890067
[TBL] [Abstract][Full Text] [Related]
20. The Beta-Carotene and Retinol Efficacy Trial: incidence of lung cancer and cardiovascular disease mortality during 6-year follow-up after stopping beta-carotene and retinol supplements.
Goodman GE; Thornquist MD; Balmes J; Cullen MR; Meyskens FL; Omenn GS; Valanis B; Williams JH
J Natl Cancer Inst; 2004 Dec; 96(23):1743-50. PubMed ID: 15572756
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
